MEDICAL SOCIETY EXPERT PANEL CALLS FOR FOSAMAX FEMUR-FRACTURE WARNING
Earlier this week, an expert panel convened by the American Society of Bone & Mineral Research ("ASBMR") reviewed the growing data which demonstrate a risk of low-energy femur fractures from long-term use of oral bisphosphonates, including Fosamax and Actonel. The report is titled: "Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research". Discussing the danger of the long-term use of bisphosphonates (BPs), the authors called upon the industry to warn about the potential risk of these atypical femur fractures: "Atypical femoral fractures are of concern and more information is urgently needed, both to assist in identifying patients at particular risk and to guide decision-making about duration of BP therapy. Physicians and patients should be made aware of the possibility of atypical femoral fractures and of the potential for bilaterality, through a change in labeling of BPs."
Levin, Papantonio was the first law firm in the country to file a lawsuit on behalf of a Fosamax patient who suffered a low-energy femur fracture and has been the leader involved in litigation against the manufacturer of Fosamax, Merck & Company, since late 2005. View WSJ article If you believe you have suffered a low-energy femur fracture as a result of taking Fosamax or Actonel, please click here for a free case evaluation.Downlaod PDF
